评估基于风险的数据监测对儿科多中心随机对照试验结果的影响
Renate Le Marsney1, Kerry Johnson1,2, Jenipher Chumbes Flores3
1Children's Intensive Care Research Program, Child Health Research Centre, The University of Queensland, South Brisbane, QLD, Australia.
Clinical trials (London, England)
|February 29, 2024
概括
在儿科心脏手术试验中,有针对性的源数据验证,尽管投入了大量的时间,但没有影响结果. 这表明,在某些临床试验监测环境中,减少对源数据验证的重视可能是适当的.
科学领域:
- 临床试验 临床试验
- 心血管外科心血管外科
- 儿科医学 儿科医学
背景情况:
- 监管指南主张在临床试验中进行基于风险的监测.
- 有关有效实施基于风险的监测活动的证据有限.
- 本研究探讨了儿童心脏手术试验中基于风险的监测的效率和影响.
研究的目的:
- 评估基于风险的监测方法的效率和影响.
- 在多中心随机对照试验中评估目标源数据验证.
- 为优化临床试验监测策略提供证据.
主要方法:
- 一个多中心随机对照试验的二次分析.
- 实施了针对性的源数据验证,作为基于风险的监测的一部分.
- 计算的监控持续时间和源到数据库的错误率.
- 进行了监测,未监测和模拟试验数据集的比较.
主要成果:
- 验证了1,282名参与者的106,749个数据点.
- 总监测时间为365小时 (平均10分钟/参与者).
- 从源到数据库的总体错误率为3.1%,对试验结果的影响最小.
- 模拟数据集显示,减少验证或队列规模对结果的影响最小.
结论:
- 尽管有时间成本,但有针对性的源数据验证并没有影响研究结果.
- 这项评估支持在特定情况下减少对源数据验证作为主要监测活动的重视.
- 为具有成本效益的临床试验监测的证据基础做出贡献.
相关概念视频
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
126
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
126
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Hazard Ratio
121
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
121
Comparing the Survival Analysis of Two or More Groups
186
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
186
Relative Risk
167
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
167
Kaplan-Meier Approach
137
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
137


